IMNM Immunome, Inc.

Immunome, Inc. operates as a transformative immuno-oncology company. It creates new, safe, and powerful cancer therapies by targeting stem cell and universal cancer antigens. The firm offers discovery engine that enables the simultaneous discovery of novel tumor antigens and the cognate native human antibodies that target those antigens. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Exton, PA.

$16.62
As of 12/03/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  10/01/2020
Outstanding shares:  12,100,387
Average volume:  143,568
Market cap:   $202,318,471
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    45257U108
ISIN:        US45257U1088
Sedol:      
Valuation   (See tab for details)
PE ratio:   -15.52
PB ratio:   3.67
PS ratio:   399.84
Return on equity:   -38.20%
Net income %:   -4,136.76%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy